Aura Biosciences, Inc. (AURA)Healthcare | Biotechnology | Boston, United States | NasdaqGM
7.40 USD
-0.30
(-3.896%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 7.40 |
Hot Take ↕ | Aug. 22, 2026, 3:43 a.m. EDT
The investment case for Aura Biosciences is currently broken by a severe multi-year structural decline. Despite a 'strong buy' analyst recommendation and a massive capital raise, the stock has lost nearly 60% of its value over the last three years, with every single year showing negative returns. This relentless downward trajectory suggests the market has thoroughly priced out the company's risks, rendering any current valuation metrics like P/E or book value meaningless in a traditional sense. The recent $260 million public offering, while providing liquidity, adds dilution pressure to a business burning through cash with negative free flow and no dividend support. While the technical chart shows a recent bounce off the 200-day average, the underlying fundamentals—negative returns on equity and assets, and a lack of sustained growth—do not support a long-term turnaround thesis. The options market confirms this pessimism, with heavy put buying at low strikes suggesting traders are betting on further weakness. Until the company demonstrates a clear path to profitability or a reversal in its multi-year price trend, this remains a speculative trap rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.041384 |
| AutoARIMA | 0.041512 |
| MSTL | 0.044581 |
| AutoTheta | 0.048920 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 0.67 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.743 |
| Excess Kurtosis | 0.54 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.263 |
| Market Cap | 767,415,616 |
| Forward P/E | -3.65 |
| Beta | 0.40 |
| Website | https://www.aurabiosciences.com |
As of Aug. 22, 2026, 3:43 a.m. EDT: Speculators are positioning for a significant downside move. Put volume and open interest are heavily skewed toward deep out-of-the-money strikes (e.g., $2.00), while call activity is concentrated in the money or at-the-money. The implied volatility for puts is elevated relative to calls, indicating a fear premium for further declines rather than a bullish expectation.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.17274165 |
| Address1 | 80 Guest Street |
| Address2 | 5th Floor |
| All Time High | 26.16 |
| All Time Low | 4.345 |
| Ask | 9.22 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 1,020,390 |
| Average Daily Volume3 Month | 651,620 |
| Average Volume | 651,620 |
| Average Volume10Days | 1,020,390 |
| Beta | 0.396 |
| Bid | 5.18 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 3.047 |
| City | Boston |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.4 |
| Current Ratio | 16.821 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 7.68 |
| Day Low | 7.36 |
| Debt To Equity | 5.263 |
| Display Name | Aura Biosciences |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -136,992,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.359 |
| Enterprise Value | 460,169,600 |
| Eps Forward | -2.03 |
| Eps Trailing Twelve Months | -1.67 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.2774 |
| Fifty Day Average Change | 0.12260008 |
| Fifty Day Average Change Percent | 0.016846687 |
| Fifty Two Week Change Percent | 17.274166 |
| Fifty Two Week High | 9.535 |
| Fifty Two Week High Change | -2.1349998 |
| Fifty Two Week High Change Percent | -0.22391188 |
| Fifty Two Week Low | 4.73 |
| Fifty Two Week Low Change | 2.67 |
| Fifty Two Week Low Change Percent | 0.56448203 |
| Fifty Two Week Range | 4.73 - 9.535 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,635,514,200,000 |
| Float Shares | 79,915,963 |
| Forward Eps | -2.03 |
| Forward P E | -3.6453202 |
| Free Cashflow | -56,323,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 113 |
| Fullday Change | -0.3 |
| Fullday Change Percent | -3.8961 |
| Fullday Price | 7.4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01181 |
| Held Percent Institutions | 0.94297 |
| Implied Shares Outstanding | 103,704,809 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-29 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts. |
| Long Name | Aura Biosciences, Inc. |
| Market | us_market |
| Market Cap | 767,415,616 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_100249028 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -131,011,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 797,489,981 |
| Number Of Analyst Opinions | 5 |
| Open | 7.66 |
| Operating Cashflow | -103,007,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 617 500 8864 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 7.4 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 7.7 |
| Price Hint | 2 |
| Price To Book | 2.4286184 |
| Profit Margins | 0.0 |
| Quick Ratio | 16.646 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.3 |
| Regular Market Change Percent | -3.8961 |
| Regular Market Day High | 7.68 |
| Regular Market Day Low | 7.36 |
| Regular Market Day Range | 7.36 - 7.68 |
| Regular Market Open | 7.66 |
| Regular Market Previous Close | 7.7 |
| Regular Market Price | 7.4 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 441,402 |
| Return On Assets | -0.31238002 |
| Return On Equity | -0.53485 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 103,704,809 |
| Shares Percent Shares Out | 0.0594 |
| Shares Short | 6,158,945 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 5,608,945 |
| Short Name | Aura Biosciences, Inc. |
| Short Percent Of Float | 0.0598 |
| Short Ratio | 12.94 |
| Source Interval | 15 |
| State | MA |
| Symbol | AURA |
| Target High Price | 23.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 16.6 |
| Target Median Price | 15.0 |
| Total Cash | 323,840,000 |
| Total Cash Per Share | 3.123 |
| Total Debt | 16,594,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.67 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.55095 |
| Two Hundred Day Average Change | 0.84905005 |
| Two Hundred Day Average Change Percent | 0.12960716 |
| Type Disp | Equity |
| Volume | 441,402 |
| Website | https://www.aurabiosciences.com |
| Zip | 2,135 |